MZE829
Phase 2Recruiting 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proteinuric Kidney Disease
Conditions
Proteinuric Kidney Disease
Trial Timeline
Feb 5, 2025 → Sep 1, 2026
NCT ID
NCT06830629About MZE829
MZE829 is a phase 2 stage product being developed by Maze Therapeutics for Proteinuric Kidney Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06830629. Target conditions include Proteinuric Kidney Disease.
What happened to similar drugs?
1 of 1 similar drugs in Proteinuric Kidney Disease were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06830629 | Phase 2 | Recruiting |
Competing Products
4 competing products in Proteinuric Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aliskiren + Valsartan | Novartis | Approved | 35 |
| Inaxaplin | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-147 + Placebo | Vertex Pharmaceuticals | Phase 2/3 | 45 |
| sparsentan + No sparsentan | Travere Therapeutics | Phase 1 | 30 |